

## SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOLUME XI

## AUTHOR INDEX

- Abe T, 352  
 Aiach M, 108  
 Assarian GS, 373  
 Baker WH, 121,222  
 Ballerini G, 357  
 Bara L, 100,316  
 Barlow GH, 26  
 Bayrou B, 318  
 Bertrand H, 318  
 Bick RL, 75,213,249,330,405  
 Bienkowski MJ, 86  
 Billaud E, 316  
 Bonini F, 318  
 Brace LD, 190  
 Brinkhous KM, 337  
 Brown JM, 281,373  
 Buchanan MR, 13,133  
 Burdick M, 281  
 Castaman G, 357  
 Chen Y-H, 367  
 Chesney CM, 394  
 Choay J, 81  
 Cizmeci G, 362  
 Conrad HE, 86  
 Coyne E, 10,176  
 Davis P, 138  
 Delahousse R, 326  
 Deutsch E, 347  
 Doutremépuich C, 318,323  
 Duckert F, 342  
 Emanuele RM, 56,121  
 Engelberg H, 48  
 Fareed J, 1,17,56,89,100,112, 121,138,155,176,190,199, 227,237  
 Fernandez F, 133  
 Foloppe P, 326  
 Frick WA, 337  
 Gauthier D, 133  
 Gruel Y, 326  
 Guérois C, 326  
 Guerra S, 357  
 Hayes AC, 222  
 Hirsh J, 13  
 Hoppensteadt DA, 17,56,112, 121,199  
 Hung G-L, 40  
 Kazama M, 352  
 Kher A, 316  
 Kinoshita T, 352  
 Kitchens CS, 293  
 Koets MH, 281  
 Kumar A, 56,138,155  
 Lämmle B, 342  
 Lasker SE, 37  
 Leclerc MH, 326  
 Leroy J, 326  
 Lormeau JC, 323  
 Losito C, 29  
 Losito R, 29  
 Mammen EF, 237,281,373  
 Mardiguian J, 34  
 Marlar RA, 387  
 Matuda J, 352  
 Messmore HL, 199,208  
 Mirshahi M, 129  
 Miyakawa T, 373  
 Murano G, 75,330,373,405  
 Niwa M, 384  
 Ofosu F, 13,133  
 Ouyang C, 367  
 Owen CA, 335  
 Papinger-Fasching I, 347  
 Phillips TF, 373  
 Pifer DD, 394  
 Quilichini R, 318  
 Racanelli A, 176  
 Read MS, 337  
 Rock A, 138,155  
 Rodeghiero F, 357  
 Roncato M, 108  
 Ross ES, 213  
 Rothschild BM, 394  
 Ryu T, 352  
 Sakuragawa N, 384  
 Samama MM, 100,129,316  
 Selik NR, 281  
 Soria C, 129  
 Soria J, 129  
 Takahashi I, 352  
 Teng C-M, 367  
 Thompson LD, 394  
 Toulemonde F, 318,323,326  
 Trillou M, 34  
 Tran TH, 342  
 Ulutin ON, 362  
 Walenga JM, 17,56,89,100, 112,121,138,155,176,199  
 Walz DA, 40  
 Washington BC, 281  
 Wehrmacher WH, 218  
 Williamson K, 56  
 Wilson RF, 281  
 Wolk LW, 281  
 Yamagishi R, 384  
 Yoshimura Y, 352  
 Zbinden B, 342

## CUMULATIVE TABLE OF CONTENTS

## Number 1

HEPARIN AND ITS DERIVATIVES, PART ONE:  
BASIC AND PRECLINICAL CONSIDERATIONS

Jawed Fareed, Guest Editor

- Heparin, Its Fractions, Fragments and Derivatives: Some Newer Perspectives, Jawed Fareed, 1  
 From Heparin to Heparin Fractions and Derivatives, Erwin Coyne, 10  
 Rationale Behind the Development of Low Molecular Weight Heparin Derivatives, Jack Hirsh, Fred Ofosu, and Michael Buchanan, 13  
 In Vitro Coagulant and Amidolytic Methods for Evaluating the Activity of Heparin and a Low Molecular Weight Derivative (PK 10169), Jeanine M. Walenga, Jawed Fareed, and Debra A. Hoppensteadt, 17  
 The Determination of Molecular Weight Distributions on Heparin Samples, Grant H. Barlow, 26  
 Molecular Weight of Heparin Versus Biologic Activity: Some Additional Considerations, Ray Losito and Carine Losito, 29  
 An Investigation of the Functional Role of the Carboxylic Groups of Heparin: Affinity for Antithrombin III and Anti-Xa Activity of Selectively Carboxyl Esterified Heparin, Jean Mardiguian and Michele Trillou, 34  
 Low Molecular Weight Heparin-Like Preparations with Oral Activity, Sigmund E. Lasker, 37  
 In Vivo Studies on the Binding of Heparin and Its Fractions with Platelet Factor 4, Daniel A. Walz and Guo-Long Hung, 40  
 Heparin, Heparin Fractions, and the Atherosclerotic Process, Hyman Engelberg, 48

## Studies on the Antithrombotic Effects and Pharmacokinetics of

Heparin Fractions and Fragments, Jawed Fareed, Jeanine M. Walenga, Karen Williamson, R. Martin Emanuele, Arvind Kumar, and Debra A. Hoppensteadt, 56

Abstracts of Current Literature, Genesio Murano and Rodger L. Bick, 75

## Number 2

HEPARIN AND ITS DERIVATIVES, PART TWO:  
APPLIED ASPECTS AND FUTURE CONSIDERATIONS

Jawed Fareed, Guest Editor

- Biologic Studies on Chemically Synthesized Pentasaccharide and Tetrasaccharide Fragments, Jean Choay, 81  
 Oligosaccharides Formed by Treatment of Heparin with Nitrous Acid, Michael J. Bienkowski and H. Edward Conrad, 86  
 Preliminary Biochemical and Pharmacologic Studies on a Chemically Synthesized Pentasaccharide, Jeanine M. Walenga and Jawed Fareed, 89  
 Amidolytic Antifactor Xa Assays in the Laboratory Evaluation of Heparin and Low Molecular Weight Fractions, Jeanine M. Walenga, Lucienne Bara, Meyer M. Samama, and Jawed Fareed, 100  
 Practical Considerations on the Measurement of Low Molecular Weight Heparin Anti-Xa Activity, Martine Aiach and Martine Roncato, 108  
 Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its Fractions, Debra A. Hoppensteadt, Jeanine M. Walenga, and Jawed Fareed, 112

## SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOLUME XI

## AUTHOR INDEX

- Abe T, 352  
 Aiach M, 108  
 Assarian GS, 373  
 Baker WH, 121,222  
 Ballerini G, 357  
 Bara L, 100,316  
 Barlow GH, 26  
 Bayrou B, 318  
 Bertrand H, 318  
 Bick RL, 75,213,249,330,405  
 Bienkowski MJ, 86  
 Billaud E, 316  
 Bonini F, 318  
 Brace LD, 190  
 Brinkhous KM, 337  
 Brown JM, 281,373  
 Buchanan MR, 13,133  
 Burdick M, 281  
 Castaman G, 357  
 Chen Y-H, 367  
 Chesney CM, 394  
 Choay J, 81  
 Cizmeci G, 362  
 Conrad HE, 86  
 Coyne E, 10,176  
 Davis P, 138  
 Delahousse R, 326  
 Deutsch E, 347  
 Doutremépuich C, 318,323  
 Duckert F, 342  
 Emanuele RM, 56,121  
 Engelberg H, 48  
 Fareed J, 1,17,56,89,100,112, 121,138,155,176,190,199, 227,237  
 Fernandez F, 133  
 Foloppe P, 326  
 Frick WA, 337  
 Gauthier D, 133  
 Gruel Y, 326  
 Guérois C, 326  
 Guerra S, 357  
 Hayes AC, 222  
 Hirsh J, 13  
 Hoppensteadt DA, 17,56,112, 121,199  
 Hung G-L, 40  
 Kazama M, 352  
 Kher A, 316  
 Kinoshita T, 352  
 Kitchens CS, 293  
 Koets MH, 281  
 Kumar A, 56,138,155  
 Lämmle B, 342  
 Lasker SE, 37  
 Leclerc MH, 326  
 Leroy J, 326  
 Lormeau JC, 323  
 Losito C, 29  
 Losito R, 29  
 Mammen EF, 237,281,373  
 Mardiguian J, 34  
 Marlar RA, 387  
 Matuda J, 352  
 Messmore HL, 199,208  
 Mirshahi M, 129  
 Miyakawa T, 373  
 Murano G, 75,330,373,405  
 Niwa M, 384  
 Ofosu F, 13,133  
 Ouyang C, 367  
 Owen CA, 335  
 Papinger-Fasching I, 347  
 Phillips TF, 373  
 Pifer DD, 394  
 Quilichini R, 318  
 Racanelli A, 176  
 Read MS, 337  
 Rock A, 138,155  
 Rodeghiero F, 357  
 Roncato M, 108  
 Ross ES, 213  
 Rothschild BM, 394  
 Ryu T, 352  
 Sakuragawa N, 384  
 Samama MM, 100,129,316  
 Selik NR, 281  
 Soria C, 129  
 Soria J, 129  
 Takahashi I, 352  
 Teng C-M, 367  
 Thompson LD, 394  
 Toulemonde F, 318,323,326  
 Trillou M, 34  
 Tran TH, 342  
 Ulutin ON, 362  
 Walenga JM, 17,56,89,100, 112,121,138,155,176,199  
 Walz DA, 40  
 Washington BC, 281  
 Wehrmacher WH, 218  
 Williamson K, 56  
 Wilson RF, 281  
 Wolk LW, 281  
 Yamagishi R, 384  
 Yoshimura Y, 352  
 Zbinden B, 342

## CUMULATIVE TABLE OF CONTENTS

## Number 1

HEPARIN AND ITS DERIVATIVES, PART ONE:  
BASIC AND PRECLINICAL CONSIDERATIONS

Jawed Fareed, Guest Editor

- Heparin, Its Fractions, Fragments and Derivatives: Some Newer Perspectives, Jawed Fareed, 1  
 From Heparin to Heparin Fractions and Derivatives, Erwin Coyne, 10  
 Rationale Behind the Development of Low Molecular Weight Heparin Derivatives, Jack Hirsh, Fred Ofosu, and Michael Buchanan, 13  
 In Vitro Coagulant and Amidolytic Methods for Evaluating the Activity of Heparin and a Low Molecular Weight Derivative (PK 10169), Jeanine M. Walenga, Jawed Fareed, and Debra A. Hoppensteadt, 17  
 The Determination of Molecular Weight Distributions on Heparin Samples, Grant H. Barlow, 26  
 Molecular Weight of Heparin Versus Biologic Activity: Some Additional Considerations, Ray Losito and Carine Losito, 29  
 An Investigation of the Functional Role of the Carboxylic Groups of Heparin: Affinity for Antithrombin III and Anti-Xa Activity of Selectively Carboxyl Esterified Heparin, Jean Mardiguian and Michele Trillou, 34  
 Low Molecular Weight Heparin-Like Preparations with Oral Activity, Sigmund E. Lasker, 37  
 In Vivo Studies on the Binding of Heparin and Its Fractions with Platelet Factor 4, Daniel A. Walz and Guo-Long Hung, 40  
 Heparin, Heparin Fractions, and the Atherosclerotic Process, Hyman Engelberg, 48

## Studies on the Antithrombotic Effects and Pharmacokinetics of

Heparin Fractions and Fragments, Jawed Fareed, Jeanine M. Walenga, Karen Williamson, R. Martin Emanuele, Arvind Kumar, and Debra A. Hoppensteadt, 56

Abstracts of Current Literature, Genesio Murano and Rodger L. Bick, 75

## Number 2

HEPARIN AND ITS DERIVATIVES, PART TWO:  
APPLIED ASPECTS AND FUTURE CONSIDERATIONS

Jawed Fareed, Guest Editor

- Biologic Studies on Chemically Synthesized Pentasaccharide and Tetrasaccharide Fragments, Jean Choay, 81  
 Oligosaccharides Formed by Treatment of Heparin with Nitrous Acid, Michael J. Bienkowski and H. Edward Conrad, 86  
 Preliminary Biochemical and Pharmacologic Studies on a Chemically Synthesized Pentasaccharide, Jeanine M. Walenga and Jawed Fareed, 89  
 Amidolytic Antifactor Xa Assays in the Laboratory Evaluation of Heparin and Low Molecular Weight Fractions, Jeanine M. Walenga, Lucienne Bara, Meyer M. Samama, and Jawed Fareed, 100  
 Practical Considerations on the Measurement of Low Molecular Weight Heparin Anti-Xa Activity, Martine Aiach and Martine Roncato, 108  
 Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its Fractions, Debra A. Hoppensteadt, Jeanine M. Walenga, and Jawed Fareed, 112

**Usefulness of Fibrinopeptide A Generation Tests in Experimental and Clinical Studies with Low Molecular Weight Heparin Fractions**, R. Martin Emanuele, Jawed Fareed, Jeanine M. Walenga, Debra A. Hoppensteadt, and William H. Baker, 121

**Markers of Fibrinogen Derivatives Used in Clinical Investigation**, Jeannette Soria, Claudine Soria, Massoud Mirshahi, and Meyer M. Samama, 129

**Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate**, Frederick A. Ofori, Francoise Fernandez, Doris Gauthier, and Michael R. Buchanan, 133

**A Primate Model (Macaca Mulatta) to Study the Pharmacokinetics of Heparin and Its Fractions**, Jawed Fareed, Arvind Kumar, Alice Rock, Jeanine M. Walenga, and Paul Davis, 138

**A Modified Stasis Thrombosis Model to Study the Antithrombotic Actions of Heparin and Its Fractions**, Jawed Fareed, Jeanine M. Walenga, Arvind Kumar, and Alice Rock, 155

**Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments**, Adrienne Racanelli, Jawed Fareed, Jeanine M. Walenga, and Erwin Coyne, 176

**An Objective Assessment of the Interaction of Heparin and Its Fractions with Human Platelets**, Larry D. Brace and Jawed Fareed, 190

**Studies on the Profibrinolytic Actions of Heparin and Its Fractions**, Jawed Fareed, Jeanine M. Walenga, Debra A. Hoppensteadt, and Harry L. Messmore, 199

**Clinical Use of Heparin Fractions, Fragments, and Heparinoids**, Harry L. Messmore Jr., 208

**Clinical Use of Intrapulmonary Heparin**, Rodger L. Bick and Elizabeth S. Ross, 213

**Heparin Fractions and Derivatives**, William H. Wehrmacher, 218

**Heparin Prophylaxis Trials of Venous Thrombosis: A Critical Review**, Andrew C. Hayes and William H. Baker, 222

**Development of Heparin Fractions: Some Overlooked Considerations**, Jawed Fareed, 227

**Abstracts of a Symposium on Heparin and Related Substances**, Jawed Fareed and Eberhard F. Mammen, 237

### Number 3

#### SELECTED TOPICS IN THROMBOSIS AND HEMOSTASIS Rodger L. Bick, Guest Editor

**Hemostasis Defects Associated with Cardiac Surgery, Prosthetic Devices, and Other Extracorporeal Circuits**, Rodger L. Bick, 249

**Hemostasis Changes During Cardiopulmonary Bypass Surgery**, Eberhard F. Mammen, Mark H. Koets, Bruce C. Washington, Larry W. Wolk, Janet M. Brown, Michael Burdick, Nancy R. Selik, and Robert F. Wilson, 281

**Concept of Hypercoagulability: A Review of its Development, Clinical, Application, and Recent Progress**, Craig S. Kitchens, 293

**Increased Anti-Xa Bioavailability for a Low Molecular Weight Heparin (PK 10169) Compared with Unfractionated Heparin**,

Lucienne Bara, Elaine Billaud, Andre Kher, and Meyer Samama, 316

**In Vivo Neutralization of Low-Molecular Weight Heparin Fraction CY 216 by Protamine**, Christian Doutremépuich, Francois Bonini, Francis Toulemonde, Henry Bertrand, Bertrand Bayrou, and Raymond Quilichini, 318

**Oral Administration of Low Molecular Weight Heparin Fractions in Rabbits**, Christian Doutremépuich, Francis Toulemonde, and Jean Claude Lormeau, 323

**Treatment of Heparin-Associated Thrombocytopenia and Thrombosis with Low Molecular Weight Heparin (CY 216)**, Jean Leroy, M.H. Leclerc, B. Delahousse, C. Guérois, P. Foloppe, Y. Gruel, and Francis Toulemonde, 326

**Abstracts of Current Literature**, Genesio Murano and Rodger L. Bick, 330

### Number 4

#### RECENT ADVANCES IN BLOOD COAGULATION Eberhard F. Mammen, Guest Editor

**Historical Remarks**, Charles A. Owen Jr., 335

**Determinants of von Willebrand Factor Activity Elicited by Ristocetin and Botrocetin: Studies on a Human von Willebrand Factor-Binding Antibody**, Kenneth M. Brinkhous, William A. Fricke, and Marjorie S. Read, 337

**Methodology and Clinical Significance of Heparin Cofactor II: Probable Heparin Cofactor II Deficiency in a Patient with Cerebrovascular Thrombosis**, Tri H. Tran, Brigitte Zbinden, Bernhard Lämmle, and François Duckert, 342

**Protein C Deficiency in Austria**, Ingrid Pabinger-Fasching and Erwin Deutsch, 347

**Occurrence of AIDS in Hemophiliacs in Japan**, Takeshi Abe, Mutsuyoshi Kazama, Tadatashi Kinoshita, Juzo Matuda, Yuichi Yoshimura, Tomiko Ryu, and Ichiro Takahashi, 352

**A Contribution to the Pathology of Acquired Plasma Factor XIII Deficiency**, Giorgio Ballerini, Severino Guerra, Francesco Rodeghiero, and Giancarlo Castaman, 357

**Alteration of Prostanoids in Atherosclerosis**, Orhan N. Ulutin and G. Cizmeci, 362

**Effect of Russell's Viper Venom Phospholipase A on Blood Coagulation and Platelet Aggregation**, Che-Ming Teng, Yen-Hui Chen, and Chaohou Ouyang, 367

**Human Antithrombin Concentrates and Experimental Disseminated Intravascular Coagulation**, Eberhard F. Mammen, Teruo Miyakawa, Thomas F. Phillips, Gary S. Assarian, Janet M. Brown, and Genesio Murano, 373

**Studies on the Purification and Characteristics of Histidine-Rich Glycoprotein**, Nobuo Sakuragawa, Masahiro Niwa, and Ryoichi Yamagishi, 384

**Protein C in Thromboembolic Disease**, Richard A. Marlar, 387

**Perturbation of Protease Inhibitors and Substrates in Inflammatory Arthritis**, Bruce M. Rothschild, Lee D. Thompson, D. David Pifer, and Carolyn M. Chesney, 394

**Abstracts of Current Literature**, Genesio Murano and Rodger L. Bick, 405